-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40

Benzinga·11/05/2026 15:31:21
Listen to the news
Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price target from $41 to $40.